Careers  |  Sign In  |  Register  |   Twitter

Novartis Psoriasis Drug Offers Safe Treatment Option

Staff reviewers at the FDA have confirmed that Novartis‘ new psoriasis drug, secukinumab, poses no major safety issues to patients. According to Reuters, secukinumab (AIN457) is expected to lead the way in immunosuppresant therapy, a class of drugs that targets interleukin-17 (IL-17), one of the main causes of psoriasis. With the psoriasis market expected to more than double in the next decade, Kepler Chevreux analysts forecast peak sales of $701 million by 2020. Novartis’ competition in other IL-17 drugs that may soon hit the market include Eli Lilly‘s ixekizumab and Amgen and AstraZeneca‘s brodalumab.

Read the article published by Reuters.